Needham Boosts Veracyte Target to $57 on New Diagnostic Test Data
VCYT•Needham raised its Veracyte price target to $57, implying 17.8% upside, driven by U.S. launch of Prosigna Breast Risk of Recurrence test and positive Decipher Prostate trial data. Veracyte’s shares jumped 5.1% to $48.68, approaching its 52-week high of $50.71 ahead of further diagnostic rollout.
1. Analyst Raises Price Target to $57
On June 1, Needham increased Veracyte’s price target from the prior level to $57, reflecting confidence in the company’s diagnostic pipeline. At the time of the raise, shares traded at $48.38, suggesting a potential 17.81% gain and valuing the firm at roughly $3.88 billion.
2. U.S. Launch of Prosigna Breast Risk Test
Veracyte recently rolled out its Prosigna Breast Risk of Recurrence test in the U.S., offering a genomic tool that guides chemotherapy decisions for early-stage breast cancer patients. This launch follows the landmark OPTIMA trial, which demonstrated the test’s ability to safely identify patients who can avoid chemotherapy.
3. Positive ENZAMET Data for Decipher Prostate
The company announced favorable results from the ENZAMET trial of its Decipher Prostate test, showing it can pinpoint men with metastatic prostate cancer who benefit from added chemotherapy. This data covers approximately 334,000 diagnoses annually and marks a key advance in personalized cancer care.
4. Stock Performance Nears 52-Week High
Veracyte’s shares rose 5.06% to $48.68 and are trading close to their 52-week high of $50.71, after bouncing back from a low of $22.61 over the past year. The strong market response underscores investor enthusiasm for the company’s expanding diagnostic offerings.
